TumorPASSAGENCT07092800
Care Pathways and Disparities in Care for Older Patients With Cancer: Typology, Determinants and Effect on Prognosis ( PASSAGE )
An observational study of Tumor and Health Services Research, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
More than half of new cases of cancer in Europe in 2022 occurred in people aged over 70. In addition to cancer, the majority of older people have one or more illnesses that may interact with the treatment decision, cancer progression, tolerance and efficacy of treatments, quality of life, care pathway and survival. Read more about this study
- Who is it for?
- Ages 70 to 130 years
- Conditions the study is for
- Tumor, Health Services Research, Causality
- How many people
- 75,000 participants
- Where
- 1 siteFrance
- Study dates
- 7 Sep 2024to 31 Aug 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 to 130 years
- All sexes
- No healthy volunteers
- Older adult
Study population: elderly cancer patients treated at AP-HP
Who may be able to join
- Patients aged 70 or over,
- Having at least one International Classification of Disease, 10th revision (ICD-10) for solid cancer recorded as principal diagnostic or related,
- During treatment in an AP-HP hospital,
- Between 01/08/2017 and 31/07/2023.
Who cannot join
- opposition to the reuse of healthcare data
Trial locations and contacts
1 site in 1 country.
About this study
More than half of new cases of cancer in Europe in 2022 occurred in people aged over 70. In addition to cancer, the majority of older people have one or more illnesses that may interact with the treatment decision, cancer progression, tolerance and efficacy of treatments, quality of life, care pathway and survival. Furthermore, cancer treatments are most often evaluated in middle-aged subjects without severe disease, so the real-life management of older patients is often empirical.
The general objective of the PASSAGE project is to assess the hospital care pathways of older patients with cancer treated at AP-HP by evaluating key elements of these pathways from both geriatric and therapeutic perspectives. Characterizing these care trajectories will help identify the most vulnerable patient profiles and potential disparities in access to care, with the goal of optimizing the management of elderly patients with cancer.
The aims of this research are 1) to provide a better description of trends in the management of older cancer patients in routine clinical practice, and 2) to assess the impact of frailty, multimorbidity and the management of these patients on the prognosis of the disease.
- Conditions
- Tumor, Health Services Research, Causality, Geriatric Assessment, Aged, Cancer
- Keywords
- Frailty, care pathways, cancer, ageing
- Medical subject headings
- Neoplasms, Frailty
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients aged 70 or over with solid cancer | The following inclusion criteria will be applied to identify the study population: * Patients aged 70 or over, * Having at least one International Classification of Disease, 10th revision (ICD-10) code for solid cancer recorded as principal diagnostic or related, * During treatment in an AP-HP hospital, * Between 01/08/2017 and 31/07/2023. |
What is being measured
The primary outcome is the main question the study is designed to answer.
type of care pathway
The primary endpoint is the type of care pathway as identified by longitudinal clustering analysis of Electronic Health Record (EHR) data in the year following diagnosis (medical diagnoses, procedures, admissions, treatment received),.
Measured: from cancer diagnosis during a year of follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2025
- Study start7 Sep 2024
- Primary completion31 Aug 2028 (estimated)
- Study completion31 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TumorStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 75,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Collaborators
- Inria, the French National Institute for computer science and applied mathematics, CentraleSupelec School of Engineering
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07092800
- Sponsor's protocol ID
- APHP240996
- Other IDs
- CSE-24-08_PASSAGE
- Acronym
- PASSAGE
- Status last verified
- Jul 2025
- First submitted
- 22 Jul 2025
- Last updated
- 30 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data are available upon reasonable request. Proposals should be directed to ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP), Department for Clinical Research, Innovation (DRCI) represented by Mr Milan LAZAREVIC , Director. To gain access, data requestors will need to sign a data transfert agreement with the sponsor
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Care Pathways and Disparities in Care for Older Patients With Cancer: Typology, Determinants and Effect on Prognosis ( PASSAGE )
- ClinicalTrials.gov ID
- NCT07092800
- Acronym / sponsor ID
- PASSAGE / APHP240996
- Conditions
- Tumor, Health Services Research, Causality, Geriatric Assessment, Aged, Cancer
- Keywords
- Frailty, care pathways, cancer, ageing
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 75,000 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- Inria, the French National Institute for computer science and applied mathematics, CentraleSupelec School of Engineering
- Study start
- 7 Sep 2024 (actual)
- Primary completion
- 31 Aug 2028 (estimated)
- Study completion
- 31 Aug 2028 (estimated)
- First posted
- 30 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
More than half of new cases of cancer in Europe in 2022 occurred in people aged over 70. In addition to cancer, the majority of older people have one or more illnesses that may interact with the treatment decision, cancer progression, tolerance and efficacy of treatments, quality of life, care pathway and survival. Furthermore, cancer treatments are most often evaluated in middle-aged subjects without severe disease, so the real-life management of older patients is often empirical.
The general objective of the PASSAGE project is to assess the hospital care pathways of older patients with cancer treated at AP-HP by evaluating key elements of these pathways from both geriatric and therapeutic perspectives. Characterizing these care trajectories will help identify the most vulnerable patient profiles and potential disparities in access to care, with the goal of optimizing the management of elderly patients with cancer.
The aims of this research are 1) to provide a better description of trends in the management of older cancer patients in routine clinical practice, and 2) to assess the impact of frailty, multimorbidity and the management of these patients on the prognosis of the disease.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients aged 70 or over with solid cancer | – | –The following inclusion criteria will be applied to identify the study population: * Patients aged 70 or over, * Having at least one International Classification of Disease, 10th revision (ICD-10) code for solid cancer recorded as principal diagnostic or related, * During treatment in an AP-HP hospital, * Between 01/08/2017 and 31/07/2023. |
Who may qualify
- Ages
- 70 to 130 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- elderly cancer patients treated at AP-HP
Key inclusion criteria (4 listed)
- Patients aged 70 or over,
- Having at least one International Classification of Disease, 10th revision (ICD-10) for solid cancer recorded as principal diagnostic or related,
- During treatment in an AP-HP hospital,
- Between 01/08/2017 and 31/07/2023.
Key exclusion criteria (1 listed)
- opposition to the reuse of healthcare data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
type of care pathway
Time frame: from cancer diagnosis during a year of follow-up
The primary endpoint is the type of care pathway as identified by longitudinal clustering analysis of Electronic Health Record (EHR) data in the year following diagnosis (medical diagnoses, procedures, admissions, treatment received),.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2025.
- Individual participant dataSharing planned: No. Data are available upon reasonable request. Proposals should be directed to ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP), Department for Clinical Research, Innovation (DRCI) represented by Mr Milan LAZAREVIC , Director. To gain access, data requestors will need to sign a data transfert agreement with the sponsor
Related trials for Tumor
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tumor and Health Services Research, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
type of care pathway (time frame: from cancer diagnosis during a year of follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2025.